Compare UP & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UP | ENTX |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.2M | 147.4M |
| IPO Year | 2020 | 2015 |
| Metric | UP | ENTX |
|---|---|---|
| Price | $3.13 | $3.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 75.1K | ★ 627.5K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | ★ $736,495,000.00 | $42,000.00 |
| Revenue This Year | $193.34 | N/A |
| Revenue Next Year | $12.65 | N/A |
| P/E Ratio | ★ N/A | $14.05 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $0.91 |
| 52 Week High | $10.09 | $4.20 |
| Indicator | UP | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.29 | 63.60 |
| Support Level | $0.47 | $2.64 |
| Resistance Level | $4.01 | $3.26 |
| Average True Range (ATR) | 0.22 | 0.23 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 37.74 | 92.73 |
Wheels Up Experience Inc is a provider of on-demand private aviation. The company offers a private aviation solution with a large and diverse aircraft fleet, delivered through a mix of charter solutions and its membership program that utilizes its controlled aircraft fleet and a network of safety-vetted charter operators. Through its partnership firm, it provides members and customers with an offering across private and premium commercial travel. It generates the majority of its revenue from member and customer flights through its membership program and charter solutions, as well as from membership fees and other activities and services, including group charter flights, cargo flights, and special missions. Geographically, the company generates maximum revenue from the United States.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.